Abnormal PSA tests: Delays in referral

Australian Family Physician

Volumn 37, Issue 1-2, 2008, Pages 84-88

  Stapleton, Alan M F ^a   Johns, Richard L ^b   Kopsaftis, Tina ^a   Tamblyn, David J ^a   Pinnock, Carole B ^b  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b Adelaide W Div of General Practice   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; BLOOD; HUMAN; MALE; PATIENT REFERRAL; PRIMARY HEALTH CARE; PROSTATE TUMOR; STATISTICS; TIME;

AGE FACTORS; AGED; HUMANS; MALE; PRIMARY HEALTH CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; TIME FACTORS;

EID: 40649088655     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Australian Institute of Health and Welfare. Australia's health 2006. Canberra: AIHW, 2006.
2. Australian Health Technology Advisory Committee. Prostate cancer screening. Canberra: AHTAC, 1996.
3. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
4. Baade PD, Steginga SK, Pinnock CB, Aitken JF, Communicating prostate cancer risk: what should we be telling our patients? Med J Aust 2005;182:472-5.
5. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
6. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998;159:1368-72.
7. Urological Society of Australia and New Zealand. PSA testing for prostate cancer, 1999. Available at www.urosoc.org.au/consumer_health/ index.jsp?a=1126157272 [Accessed 21 August 2007].
8. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 6th edn. South Melbourne: The RACGP, 2005.
9. Carrière P, Baade P, Newman B, Aitken J, Janda M. Cancer screening in Queensland men. Med J Aust 2007;186:404-7.
10. Gattellari M, Young JM, Ward JE. GP and patient predictors of PSA screening in Australian general practice. Fam Pract 2003;20:294-303.
11. Stone CA, May FW, Pinnock CB, Elwood M, Rowett DS. Prostate cancer, the PSA test and academic detailing in general practice: an economic evaluation. Aust N Z J Public Health 2005;29:349-57.
12. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New Engl J Med 2004;350:2239-46.
13. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-5.
14. Schröder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006;49:460-5.
15. Raaijmakers R, Wildhagen MF, Ito K et al. Prostate specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 2004;63:316-20.
16. Parekh DJ, Ankerst DP, Higgins BA et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006;68:1152-5.
17. National Cancer Institute. Prostate cancer risk calculator, 2006. Available at www.compass.fhcrc.org/edrnnci/bin/calculator/ main.asp?t=prostate&sub=disclaimer&v=prostate&m=&x= Prostate%20Cancer [Accessed 21 August 2007].
18. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer early detection, 2007. Available at www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf [Accessed 21 July 2007].
19. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101.
20. Andrews SF, Horwitz EM, Feigenberg SJ, et al. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer 2005;104:299-304.
21. Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H. Reasonable delay of surgical treatment in men with localized prostate cancer: impact on prognosis? Eur Urol 2005;47:756-60.
22. Khan MA, Mangold MA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long term cancer control for clinically localized prostate cancer. J Urol 2004;172:1835-9.
23. Saad F, Finelli A, Dranitsaris G, et al. Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol 2006;13(Suppl 3):16-24.
24. Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2006;106: 576-80.
25. Krahn MD, Bremner KE, Asaria J, et al. The ten year rule revisited: accuracy of clinicians- estimates of life expectancy in patients with localized prostate cancer. Urology 2002;60:258-63.
26. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
27. Loeb S, Gonzalez CM, Roehl KA, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006;175:902-6.
28. Aleman M, Karakiewicz PI, Kupelian P, et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 2003;62:70-4.
29. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 2006;51:659-64.
30. Loeb S, Roehl KA, Catalona WJ, Nadler RB. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007;177:899-902.